News

Sagimet Biosciences and Ascletis Team Up for Acne Treatment

Sagimet Biosciences and Ascletis Team Up for Acne Treatment

Sagimet Biosciences Partners with Ascletis for Acne Therapy

Sagimet Biosciences Inc. (NASDAQ: SGMT), a clinical-stage biopharmaceutical innovator, has announced exciting developments! The company specializes in creating new therapies that target metabolic and fibrotic pathways to address various health conditions. Recently, their partner Ascletis Pharma Inc. received acceptance from China’s National Medical Products Administration (NMPA) for a New Drug Application (NDA) concerning denifanstat, a promising treatment for moderate to severe acne.

What is Denifanstat?

Denifanstat is an oral small molecule fatty acid synthase (FASN) inhibitor that Ascletis has been developing specifically for the acne market in China under the project name ASC40. This innovative treatment has shown significant effectiveness in clinical trials, addressing acne vulgaris while also being well-tolerated by patients. Sagimet is concurrently advancing denifanstat as a treatment for metabolic dysfunction associated with steatohepatitis (MASH) worldwide.

Clinical Trial Success

The NDA submitted by Ascletis is built upon successful data from their Phase 3 clinical trial, which assessed denifanstat's efficacy in treating moderate to severe acne. Impressively, the results indicated that the treatment successfully met all its primary and secondary endpoints, demonstrating both its effectiveness and safety profile.

About Sagimet Biosciences

Sagimet is focused on pioneering treatments through innovative research. Their platform includes developing FASN inhibitors, which are aimed at correcting metabolic and fibrotic issues often caused by the excessive production of palmitate, a fatty acid. Denifanstat has not only been effective in clinical trials for acne but has also shown promise in treating metabolic disorders in other studies.

Future Directions for Sagimet

Sagimet is actively working on future opportunities for denifanstat and other compounds. A combination therapy involving denifanstat and resmetirom is under investigation in a Phase 1 PK clinical trial and specifically targets cirrhotic patients with F4-stage MASH. Additionally, TVB-3567, another oral FASN inhibitor aimed at treating acne, is currently in first-in-human trials, which shows Sagimet's commitment to expanding its portfolio and addressing critical health issues.

Investor and Media Contacts

Sagimet Biosciences continues to enhance its communication with investors and the media. For those seeking further details about the company's developments, Joyce Allaire from LifeSci Advisors is the investor contact.

Contact Information

To reach Joyce Allaire, email: JAllaire@LifeSciAdvisors.com.

The media contact is Michael Fitzhugh, who may be reached via email at mfitzhugh@lifescicomms.com.

Frequently Asked Questions

What is denifanstat?

Denifanstat is an oral medication developed by Sagimet and its partner Ascletis for the treatment of moderate to severe acne.

Who is collaborating with Sagimet Biosciences?

Ascletis Pharma Inc. is the license partner working with Sagimet on denifanstat.

What are the potential applications of denifanstat?

Aside from treating acne, denifanstat is also being studied for metabolic dysfunction associated with steatohepatitis (MASH).

What is the status of clinical trials for denifanstat?

Denifanstat has met all primary and secondary endpoints in its multi-phase clinical trials and has received regulatory acceptance for further development.

How can investors learn more about Sagimet's activities?

Investors can contact Joyce Allaire at LifeSci Advisors for more information about Sagimet’s developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 18

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
JiMMYBAR! Expands Creatine Market with Target Launch

Updated Category News Views 17

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Continue Reading
ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 10

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

Updated Category News Views 9

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Continue Reading
Charter Next Generation Unveils Gen 2 MDO-PE Films

Updated Category News Views 9

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 13

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading
Skandia's Soundproofing Kit Expands to Brazil's Skies

Updated Category News Views 11

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Continue Reading
TA Services Strengthens U.S.-Mexico Freight Operations

Updated Category News Views 12

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 10

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
Epic Political Thriller Explores Humanity's Future

Updated Category News Views 10

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Continue Reading

Top 5 Most Recently Viewed Articles

Centrus Energy's Upcoming Conference Call: What to Expect

Updated Category News Views 150

Upcoming Conference Call by Centrus Energy Corp. Centrus Energy Corp. (NYSE American: LEU) is set to engage with shareholders and the financial community during its quarterly conference call on February 7, 2025, at 8:30 a.m. ET. This call offers vital insights into the company's financial performance and future direction. Details of the Earnings Report During this call,...

Continue Reading
Century Communities Posts Record 2024 Results and Outlook

Updated Category News Views 350

Century Communities Reports Impressive 2024 Performance Century Communities, Inc. (NYSE: CCS), a prominent player in the homebuilding industry, has declared remarkable financial results for the fourth quarter and full year of 2024. The company achieved record net income and significant year-over-year growth across key metrics. Fourth Quarter Highlights The fourth quarter...

Continue Reading
Yamaha Guitars: Celebrating 60 Years of Innovation and Craft

Updated Category News Views 107

Yamaha Guitars Commemorates 60 Years of Excellence Yamaha has reached a remarkable milestone as it celebrates 60 years in guitar manufacturing, showcasing their dedication to artistry and innovation in the music industry. This celebration was announced at The NAMM Show 2026, where Yamaha introduced brand new products and honored its legacy. This year’s festivities...

Continue Reading
Innovative Fundraising: GCU's Commitment to Community Growth

Updated Category News Views 412

GCU's Revolutionary Fundraising Campaign: A Community-Centric Approach Grand Canyon University (NASDAQ: GCU) is embracing an extraordinary approach to fundraising, one that emphasizes community revitalization over traditional university needs. This initiative marks a significant transition for the university that resumed its nonprofit status in 2018. The campaign is set...

Continue Reading
Montreal's Innovative Modular Housing Project for the Homeless

Updated Category News Views 263

Montreal's Innovative Modular Housing Project The City of Montreal has achieved a significant milestone by launching its first modular housing project aimed at addressing homelessness. This initiative provides essential support services to offer a sustainable solution for vulnerable individuals, demonstrating a commitment to tackling the homelessness crisis effectively....

Continue Reading